A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene


Grant Data
Project Title
A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Principal Investigator
Dr Ho, James Chung Man   (Principal investigator)
Co-Investigator(s)
Dr Wong Matthew   (Co-Investigator)
Dr Lam Jamie   (Co-Investigator)
Dr Lam Chi Leung David   (Co-Investigator)
Duration
30
Start Date
2011-04-01
Completion Date
2013-09-30
Amount
606762
Conference Title
Presentation Title
Keywords
non-small cell lung cancer
Discipline
Cancer
Panel
Medicine
Grant Type
Pharmaceutical Industry - General Award
Funding Year
2010/2011
Status
On-going